Clinical value of chromosome arms 19q and 11p losses in low-grade gliomas

Neuro-Oncology

Volumn 16, Issue 3, 2014, Pages 400-408

  Alentorn, Agustí ^a   Van Thuijl, Hinke F ^c   Marie, Yannick ^a   Alshehhi, Hussa ^a,b   Carpentier, Catherine ^a   Boisselier, Blandine ^a   Laigle Donadey, Florence ^a,b   Mokhtari, Karima ^a,b   Scheinin, Ilari ^a,b,c   Wesseling, Pieter ^c,d   Ylstra, Bauke ^c   Capelle, Laurent ^a   Hoang Xuan, Khê ^a,b   Sanson, Marc ^a,b   Delattre, Jean Yves ^a,b   Reijneveld, Jaap C ^c   Idbaih, Ahmed ^a,b  

^a INSTITUT DU CERVEAU ET DE LA MOELLE ÉPINIÈRE   (France)

^b Department of Neurosurgery ^*  (France)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

biomarker; genomic array; IDH; low grade gliomas; MGMT; TP53

Indexed keywords

BIOMARKER; GENOMIC ARRAY; IDH; LOW-GRADE GLIOMAS; MGMT, TP53;

ADULT; BRAIN NEOPLASMS; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 1; CHROMOSOMES, HUMAN, PAIR 11; CHROMOSOMES, HUMAN, PAIR 19; FEMALE; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; SURVIVAL ANALYSIS;

EID: 84894226119     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/not227     Document Type: Article

References (34)

1. SmithJS, PerryA,Borell TJ, et al.Alterations ofchromosomearms1pand 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol. 2000;18(3):636-645.
2. Louis D, Ohgaki H, Wiestler O, CaveneeW.WHOClassification of Tumors of the Central Nervous System, 4th ed. Ogdensburg: Renouf Publishing Co. Ltd; 2007.
3. Ohgaki H, Kleihues P. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol. 2005;64(6):479-489.
4. Coons SW, Johnson PC, Scheithauer BW, et al. Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas. Cancer. 1997;79(7):1381-1393.
5. Bourne TD, Schiff D. Update on molecular findings, management and outcome in low-grade gliomas. Nat Rev Neurol. 2010;6(12):695-701.
6. van den Bent MJ, Looijenga LH, Langenberg K, et al. Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features. Cancer. 2003;97(5):1276-1284.
7. Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360(8):765-773.
8. Houillier C, Wang X, Kaloshi G, et al. IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas. Neurology. 2010;75(17):1560-1566.
9. Jenkins RB, Blair H, Ballman KV, et al. A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res. 2006;66(20): 9852-9861.
10. Labussière M, Idbaih A, Wang XW, et al. All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2. Neurology. 2010;74(23): 1886-1890.
11. Hartmann C, Hentschel B, Tatagiba M, et al. German Glioma Network. Molecular markers in low-grade gliomas: predictive or prognostic? Clin Cancer Res. 2011;17(13):4588-4599.
12. Kim YH, Nobusawa S, Mittelbronn M, et al. Molecular classification of low-grade diffuse gliomas. Am J Pathol. 2010;177(6):2708-2714.
13. Everhard S, Kaloshi G, Criniè re E, et al. MGMT methylation: a marker of response to temozolomide in low-grade gliomas. Ann Neurol. 2006; 60(6):740-743.
14. Komine C,Watanabe T, Katayama Y, et al. Promoter hypermethylation of the DNA repair gene O6-methylguanine-DNA methyltransferase is an independent predictor of shortened progression free survival in patients with low-grade diffuse astrocytomas. Brain Pathol. 2003; 13(2):176-184.
15. Metellus P, Coulibaly B, Colin C, et al. Absence of IDH mutation identifies a novel radiologic and molecular subtype of WHO grade II gliomas with dismal prognosis. Acta Neuropathol. 2010;120(6): 719-729.
16. Idbaih A, Marie Y, Lucchesi C, et al. BAC array CGH distinguishes mutually exclusive alterations that define clinicogenetic subtypes of gliomas. Int J Cancer. 2008;122(8):1778-1786.
17. QuillienV, LavenuA, Karayan-TaponL,et al.Comparativeassessmentof5 methods (methylation-specific polymerase chain reaction, methylight, pyrosequencing, methylation-sensitive high-resolution melting, and immunohistochemistry) to analyze O6-methylguanine-DNAmethyltranferase in a series of 100 glioblastoma patients. Cancer. 2012;118(17):4201-4211.
18. Hoang-Xuan K, Capelle L, Kujas M, et al. Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol. 2004;22(15):3133-3138.
19. Benjamini Y, Hochberg Y.Controlling the false discovery rate:Apractical and powerful approach to multiple testing. J Royal Statist Soc Series B. 1995;57(1):289-300.
20. Neuvial P, Hupé P, Brito I, et al. Spatial normalization of array-CGHdata. BMC Bioinformatics. 2006;7:264.
21. Hupé P, Stransky N, Thiery JP, Radvanyi F, Barillot E. Analysis of array CGH data: from signal ratio to gain and loss of DNA regions. Bioinformatics. 2004;20(18):3413-3422.
22. Diskin SJ, Eck T, Greshock J, et al. STAC: A method for testing the significance of DNA copy number aberrations across multiple array-CGH experiments. Genome Res. 2006;16(9):1149-1158.
23. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33(2):159-174.
24. van Thuijl HF, Ylstra B, Wü rdinger T, et al. Genetics and pharmacogenetics of diffuse gliomas. Pharmacol Ther. 2013;137(1): 78-88.
25. Ständer M, Peraud A, Leroch B, Kreth FW. Prognostic impact of TP53 mutation status for adult patients with supratentorial World Health Organization Grade II astrocytoma or oligoastrocytoma: a long-term analysis. Cancer. 2004;101(5):1028-1035.
26. Dahlback HS, Gorunova L, Brandal P, et al. Genomic aberrations in diffuse low-grade gliomas. Genes Chromosomes Cancer. 2011; 50(6):409-420.
27. Hartmann C, Meyer J, Balss J, et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol. 2009;118(4):469-474.
28. Borriello A, Caldarelli I, Bencivenga D, et al. p57(Kip2) and cancer: time for a critical appraisal. Mol Cancer Res. 2011;9(10):1269-1284.
29. Singer R, Zhao R, Barsotti AM, et al. Nuclear pore component Nup98 is a potent tumor suppressor and regulates posttranscriptional expression of select p53 target genes. Mol Cell. 2012;48(5):799-810.
30. Chu SH, Feng DF, Ma YB, et al. Promoter methylation and downregulation of SLC22A18 are associated with the development and progression of human glioma. J Transl Med. 2011;9:156.
31. Bettegowda C, Agrawal N, Jiao Y, et al. Mutations in CIC and FUBP1 contribute to human oligodendroglioma. Science. 2011;333(6048): 1453-1455.
32. Kannan K, Inagaki A, Silber J, et al. Whole-exomesequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma. Oncotarget. 2012;3(10):1194-1203.
33. Jiao Y, Killela PJ, Reitman ZJ, et al. Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas. Oncotarget. 2012;3(7):709-722.
34. Killela PJ, Reitman ZJ, Jiao Y, et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci USA. 2013;110(15): 6021-6026.